Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 72337 | 4.8709 |
09:34 ET | 16838 | 4.89 |
09:36 ET | 41714 | 4.88 |
09:38 ET | 13010 | 4.89 |
09:39 ET | 21890 | 4.89 |
09:41 ET | 34344 | 4.88 |
09:43 ET | 68734 | 4.89 |
09:45 ET | 15067 | 4.895 |
09:48 ET | 23352 | 4.885 |
09:50 ET | 27494 | 4.89 |
09:52 ET | 41873 | 4.895 |
09:54 ET | 41433 | 4.905 |
09:56 ET | 64740 | 4.905 |
09:57 ET | 4546 | 4.9 |
09:59 ET | 5436 | 4.9004 |
10:01 ET | 67076 | 4.86 |
10:03 ET | 46439 | 4.855 |
10:06 ET | 62508 | 4.8501 |
10:08 ET | 153545 | 4.835 |
10:10 ET | 27537 | 4.8199 |
10:12 ET | 19302 | 4.8 |
10:14 ET | 57998 | 4.82 |
10:15 ET | 11836 | 4.82 |
10:17 ET | 14920 | 4.81 |
10:19 ET | 67818 | 4.81 |
10:21 ET | 14947 | 4.8 |
10:24 ET | 42239 | 4.81 |
10:26 ET | 5368 | 4.81 |
10:28 ET | 33613 | 4.81 |
10:30 ET | 18509 | 4.805 |
10:32 ET | 11032 | 4.815 |
10:33 ET | 7063 | 4.815 |
10:35 ET | 30467 | 4.803 |
10:37 ET | 154844 | 4.785 |
10:39 ET | 111508 | 4.8 |
10:42 ET | 9941 | 4.79 |
10:44 ET | 88153 | 4.805 |
10:46 ET | 32514 | 4.805 |
10:48 ET | 10741 | 4.795 |
10:50 ET | 9419 | 4.79 |
10:51 ET | 9844 | 4.795 |
10:53 ET | 23051 | 4.795 |
10:55 ET | 7926 | 4.805 |
10:57 ET | 17380 | 4.7983 |
11:00 ET | 11927 | 4.8 |
11:02 ET | 10004 | 4.795 |
11:04 ET | 103457 | 4.805 |
11:06 ET | 27681 | 4.79 |
11:08 ET | 17280 | 4.79 |
11:09 ET | 55967 | 4.8 |
11:11 ET | 15199 | 4.785 |
11:13 ET | 8547 | 4.78 |
11:15 ET | 13889 | 4.77 |
11:18 ET | 25142 | 4.765 |
11:20 ET | 31109 | 4.78 |
11:22 ET | 3833 | 4.77 |
11:24 ET | 59707 | 4.765 |
11:26 ET | 11098 | 4.75 |
11:27 ET | 102667 | 4.765 |
11:29 ET | 1139 | 4.77 |
11:31 ET | 13797 | 4.765 |
11:33 ET | 69159 | 4.745 |
11:36 ET | 15750 | 4.7306 |
11:38 ET | 98045 | 4.735 |
11:40 ET | 34640 | 4.755 |
11:42 ET | 6045 | 4.755 |
11:44 ET | 24327 | 4.745 |
11:45 ET | 6553 | 4.745 |
11:47 ET | 17750 | 4.75 |
11:49 ET | 58885 | 4.755 |
11:51 ET | 11831 | 4.76 |
11:54 ET | 4419 | 4.755 |
11:56 ET | 2386 | 4.755 |
11:58 ET | 35093 | 4.755 |
12:00 ET | 12977 | 4.765 |
12:02 ET | 9702 | 4.77 |
12:03 ET | 20626 | 4.76 |
12:05 ET | 3059 | 4.75 |
12:07 ET | 22723 | 4.75 |
12:09 ET | 51276 | 4.75 |
12:12 ET | 88098 | 4.73 |
12:14 ET | 13097 | 4.735 |
12:16 ET | 35438 | 4.72 |
12:18 ET | 169476 | 4.775 |
12:20 ET | 7395 | 4.785 |
12:21 ET | 3725 | 4.78 |
12:23 ET | 16801 | 4.765 |
12:25 ET | 192541 | 4.7601 |
12:27 ET | 6906 | 4.765 |
12:30 ET | 18490 | 4.76 |
12:32 ET | 26507 | 4.76 |
12:34 ET | 7002 | 4.76 |
12:36 ET | 37168 | 4.76 |
12:38 ET | 55321 | 4.76 |
12:39 ET | 29434 | 4.76 |
12:41 ET | 148871 | 4.76 |
12:43 ET | 48630 | 4.75 |
12:45 ET | 71046 | 4.7699 |
12:48 ET | 8490 | 4.76 |
12:50 ET | 3230 | 4.755 |
12:52 ET | 14897 | 4.75 |
12:54 ET | 17470 | 4.75 |
12:56 ET | 3990 | 4.75 |
12:57 ET | 6673 | 4.75 |
12:59 ET | 52928 | 4.75 |
01:01 ET | 88560 | 4.765 |
01:03 ET | 16512 | 4.765 |
01:06 ET | 1361 | 4.765 |
01:08 ET | 2076 | 4.765 |
01:10 ET | 2688 | 4.765 |
01:12 ET | 2886 | 4.76 |
01:14 ET | 4255 | 4.76 |
01:15 ET | 2900 | 4.765 |
01:17 ET | 24685 | 4.765 |
01:19 ET | 3966 | 4.76 |
01:21 ET | 11445 | 4.76 |
01:24 ET | 150393 | 4.79 |
01:26 ET | 13485 | 4.805 |
01:28 ET | 26679 | 4.8 |
01:30 ET | 7793 | 4.815 |
01:32 ET | 7547 | 4.815 |
01:33 ET | 4521 | 4.815 |
01:35 ET | 2840 | 4.815 |
01:37 ET | 83431 | 4.825 |
01:39 ET | 9376 | 4.8 |
01:42 ET | 27653 | 4.8 |
01:44 ET | 16629 | 4.805 |
01:46 ET | 23028 | 4.8 |
01:48 ET | 3360 | 4.8 |
01:50 ET | 12400 | 4.806 |
01:51 ET | 17620 | 4.8 |
01:53 ET | 27610 | 4.8 |
01:55 ET | 45863 | 4.8 |
01:57 ET | 21689 | 4.785 |
02:00 ET | 4700 | 4.78 |
02:02 ET | 20634 | 4.79 |
02:04 ET | 6851 | 4.79 |
02:06 ET | 8934 | 4.79 |
02:08 ET | 27149 | 4.81 |
02:09 ET | 5165 | 4.8099 |
02:11 ET | 6289 | 4.805 |
02:13 ET | 26715 | 4.815 |
02:15 ET | 19043 | 4.82 |
02:18 ET | 3907 | 4.83 |
02:20 ET | 4787 | 4.825 |
02:22 ET | 21112 | 4.81 |
02:24 ET | 6387 | 4.81 |
02:26 ET | 9484 | 4.815 |
02:27 ET | 11350 | 4.81 |
02:29 ET | 15662 | 4.8 |
02:31 ET | 46268 | 4.815 |
02:33 ET | 5588 | 4.815 |
02:36 ET | 13518 | 4.81 |
02:38 ET | 15846 | 4.81 |
02:40 ET | 60309 | 4.805 |
02:42 ET | 59602 | 4.805 |
02:44 ET | 59501 | 4.8 |
02:45 ET | 17468 | 4.78 |
02:47 ET | 31276 | 4.795 |
02:49 ET | 32111 | 4.785 |
02:51 ET | 10003 | 4.78 |
02:54 ET | 11564 | 4.785 |
02:56 ET | 35605 | 4.785 |
02:58 ET | 3103 | 4.785 |
03:00 ET | 11043 | 4.785 |
03:02 ET | 8942 | 4.785 |
03:03 ET | 21531 | 4.78 |
03:05 ET | 67223 | 4.785 |
03:07 ET | 2802 | 4.785 |
03:09 ET | 663530 | 4.775 |
03:12 ET | 41461 | 4.785 |
03:14 ET | 51527 | 4.79 |
03:16 ET | 9591 | 4.7897 |
03:18 ET | 64565 | 4.785 |
03:20 ET | 63112 | 4.785 |
03:21 ET | 23930 | 4.785 |
03:23 ET | 45391 | 4.795 |
03:25 ET | 37011 | 4.785 |
03:27 ET | 2108229 | 4.78 |
03:30 ET | 58884 | 4.81 |
03:32 ET | 10721 | 4.815 |
03:34 ET | 24600 | 4.82 |
03:36 ET | 25101 | 4.835 |
03:38 ET | 44282 | 4.82 |
03:39 ET | 17755 | 4.81 |
03:41 ET | 28074 | 4.81 |
03:43 ET | 16582 | 4.805 |
03:45 ET | 234708 | 4.7887 |
03:48 ET | 68162 | 4.785 |
03:50 ET | 392315 | 4.765 |
03:52 ET | 129412 | 4.795 |
03:54 ET | 17308 | 4.795 |
03:56 ET | 345337 | 4.77 |
03:57 ET | 61088 | 4.77 |
03:59 ET | 915704 | 4.76 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 3.0B | -13.7x | --- |
Apogee Therapeutics Inc | 2.9B | -24.1x | --- |
Morphic Holding Inc | 2.8B | -16.1x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
SpringWorks Therapeutics Inc | 3.1B | -7.6x | --- |
MoonLake Immunotherapeutics | 3.2B | -62.0x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.0B |
---|---|
Revenue (TTM) | $520.0K |
Shares Outstanding | 593.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.50 |
EPS | $-0.35 |
Book Value | $0.46 |
P/E Ratio | -13.7x |
Price/Sales (TTM) | 5,691.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40,381.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.